This is just a glimpse. Want to receive every issue of Cannabis Wire Daily, our newsletter that is sent to subscribers each weekday morning, and unlimited access to

Subscribe today.

NFL is a collaborator on CBD clinical trial. 

University of Regina researchers are conducting a placebo-controlled clinical trial that will zero in on the safety of a high-CBD cannabis/hemp isolate extract in healthy adults who are “elite contact sport” competitors.

The study seeks to answer the question: “Are cannabis/hemp-based products with high CBD safe, well-tolerated and without adverse physiological and psychological dysfunction, when administered on a daily basis?”

Study participants will take a low dose of the CBD extract, with the amount increasing as the study continues, while participants will consume a placebo “before the CBD regimen.”

Various tests, including blood and saliva analysis and psychological assessments, will be conducted to monitor CBD’s effects. 

“This study is designed to investigate anti-inflammatory and neuroprotection of the CBD formulation to determine whether it can be used on a daily basis safely during the periods of intensive exercise (resistance) training during the off-season prior to competition,” the clinical trial notice reads. “The primary research hypothesis is that cannabis/hemp-based products with high CBD are safe, well-tolerated and do not cause adverse physiological and psychological dysfunction when administered on a daily basis.”

The National Football League (NFL) is a collaborator. 

The study is expected to be completed in 2026. 

Twelve AGs push DEA on rescheduling.

The AGs of 12 states wrote a letter to DEA Administrator Anne Milgram late last week to make the case for Schedule III.

“A state-regulated cannabis industry better protects consumers than the illicit marijuana market or the unregulated intoxicating hemp-derived marketplace,” they wrote. “It is critical to acknowledge that use of cannabis, especially among youth, still incurs health and safety risks. Our regulatory regimes have sought to balance the mandate to create as safe a framework as possible with the reality of these risks. Juxtaposed against the dangers of the illicit market and unregulated hemp-derived cannabinoids, moreover, we believe that there is a public health and safety mandate to protect the state-regulated industry by rescheduling cannabis to schedule III.”

The states are:

CaliforniaColoradoConnecticutDelawareIllinoisMarylandMassachusettsNevadaNewJerseyPennsylvaniaOregon and RhodeIsland.

Health Canada survey shows more people are sourcing cannabis from legal retailers.

Health Canada published the results of its 2023 Canadian Cannabis Survey. The survey is in its seventh cycle.

Some takeaways:

• Sourcing from the licensed market : The number of survey respondents who reported a “legal source as their usual source of cannabis” has significantly increased, from 37% in 2019 to to 73% in 2023, with “legal storefronts being the most common source since 2019.”   

• Driving while impaired: The number of people who reported “driving after recent use” dropped from 2018 (27%) to 2021 (16%). Since then, the number has remained unchanged, Health Canada noted. 

• Smoking: Fewer people are choosing smoking as their vehicle of consumption, though it’s still “most common method of consuming cannabis,” with 63% of respondents noting it as their preferred consumption method, followed by eating (52%), and vaping (33%). 

An excerpt from recent editions of the Cannabis Wire Daily newsletter.   Read More